biosimilars

Testing requirements are likely slowing biosimilar entries in the US
Testing requirements are likely slowing biosimilar entries in the US
RAPS.org
biosimilars
regulatory
patents
drug rebates
Flag link:
Sandoz working to overcome barriers to greater biosimilars uptake in US
Sandoz working to overcome barriers to greater biosimilars uptake in US
Biopharma Reporter
Sandoz
biosimilars
Novartis
Flag link:
Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought
Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought
Center for Biosimilars
Biocon
Mylan
Semglee
generics
insulin
diabetes
biosimilars
Flag link:
Pfizer's Unheralded Franchise That's Worth Billions of Dollars
Pfizer's Unheralded Franchise That's Worth Billions of Dollars
Motley Fool
Pfizer
biosimilars
Humira
Inflectra
Remsima
Remicade
autoimmune disease
JNJ
Flag link:
Amgen's Enbrel Patents to Be Upheld Through 2029
Amgen's Enbrel Patents to Be Upheld Through 2029
Motley Fool
psoriasis
rheumatoid arthritis
Enbrel
Novartis
biosimilars
patents
Flag link:
AbbVie's Humira defense may keep prices high, but it's still legal, judge rules
AbbVie's Humira defense may keep prices high, but it's still legal, judge rules
Fierce Pharma
AbbVie
Humira
biosimilars
patents
Flag link:
Most big commercial health plans rarely prefer biosimilars
Most big commercial health plans rarely prefer biosimilars
Beckers Hospital Review
insurers
biosimilars
Flag link:
COVID-19 restrictions send generic drug shipping costs through the roof: survey
COVID-19 restrictions send generic drug shipping costs through the roof: survey
Fierce Pharma
COVID-19
generics
biosimilars
drug manufacturing
Flag link:
Amgen/Allergan’s rituximab biosimilar could be $4bn blockbuster
Amgen/Allergan’s rituximab biosimilar could be $4bn blockbuster
Pharmaforum
Amgen
Allergan
biosimilars
Roche
rituximab
Flag link:
Biosimilar sales to reach $6.5B by 2024, study says
Biosimilar sales to reach $6.5B by 2024, study says
Beckers Hospital Review
biosimilars
Flag link:
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
Flag link:
Is Merck a Better Buy After Announcing Spinoff?
Is Merck a Better Buy After Announcing Spinoff?
Motley Fool
Merck
spinoffs
Women's Health
biosimilars
Flag link:
Lilly, Novo Nordisk Fight Insulin Biosimilars With Tweaks to FDA Draft Guidance
Lilly, Novo Nordisk Fight Insulin Biosimilars With Tweaks to FDA Draft Guidance
RAPS.org
diabetes
insulin
biosimilars
Eli Lilly
Novo Nordisk
FDA
competition
Flag link:
Bio-Thera Solutions announces positive top-line results for BAT1706, a proposed biosimilar to Avastin
Bio-Thera Solutions announces positive top-line results for BAT1706, a proposed biosimilar to Avastin
Pharmaceutical Business Review
BAT1706
Bio-Thera Solutions
Avastin
Roche
non-squamous non-small cell lung cancer
biosimilars
Flag link:
The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers
The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers
Motley Fool
FDA
FTC
drug pricing
anti-competitive scheme
biosimilars
Flag link:
Amgen, Pfizer biosimilar sales pressure top drugs
Amgen, Pfizer biosimilar sales pressure top drugs
BioPharma Dive
biosimilars
Amgen
Pfizer
Roche
Flag link:
Roche fights off biosimilar competition as new medicines' sales soar
Roche fights off biosimilar competition as new medicines' sales soar
Pharmaforum
Roche
biosimilars
earnings
Flag link:
5 years of biosimilars in the US: what have we learned?
5 years of biosimilars in the US: what have we learned?
Pharmaforum
biosimilars
cancer
autoimmune disease
Flag link:
Pfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in US
Pfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in US
Pharmaforum
Pfizer
Roche
biosimilars
Avastin
Zirabev
Herceptin
Trazimera
Rituxan
Ruxience
Flag link:
Fighting for market share, J&J expects last year's copycat pain to 'bleed into 2020'
Fighting for market share, J&J expects last year's copycat pain to 'bleed into 2020'
Fierce Pharma
JNJ
biosimilars
Velcade
Zytiga
patents
Flag link:

Pages